| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ischemic Preconditioning | 12 | 2016 | 49 | 2.360 |
Why?
|
| Brain Ischemia | 14 | 2020 | 189 | 2.250 |
Why?
|
| Seizures | 5 | 2025 | 79 | 1.850 |
Why?
|
| RNA | 3 | 2025 | 266 | 1.420 |
Why?
|
| Epilepsy | 4 | 2025 | 59 | 1.190 |
Why?
|
| Brain | 8 | 2015 | 1472 | 1.040 |
Why?
|
| Ubiquitin | 4 | 2009 | 81 | 1.040 |
Why?
|
| Proteasome Endopeptidase Complex | 4 | 2009 | 116 | 1.020 |
Why?
|
| Apoptosis Regulatory Proteins | 7 | 2013 | 161 | 0.950 |
Why?
|
| Psychophysiologic Disorders | 1 | 2025 | 8 | 0.900 |
Why?
|
| Sequence Analysis, RNA | 1 | 2025 | 115 | 0.890 |
Why?
|
| Alternative Splicing | 1 | 2025 | 94 | 0.880 |
Why?
|
| Ischemia | 4 | 2022 | 47 | 0.800 |
Why?
|
| N-Methylaspartate | 1 | 2022 | 59 | 0.750 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2022 | 135 | 0.710 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2011 | 257 | 0.630 |
Why?
|
| Stroke | 8 | 2020 | 340 | 0.610 |
Why?
|
| Membrane Proteins | 5 | 2011 | 561 | 0.550 |
Why?
|
| Post-Concussion Syndrome | 1 | 2017 | 5 | 0.540 |
Why?
|
| Electroencephalography | 6 | 2025 | 139 | 0.520 |
Why?
|
| Rats | 18 | 2022 | 3735 | 0.510 |
Why?
|
| Neurons | 10 | 2020 | 1263 | 0.510 |
Why?
|
| Animals | 34 | 2024 | 16992 | 0.470 |
Why?
|
| Hypertension | 1 | 2022 | 835 | 0.470 |
Why?
|
| Genomics | 3 | 2017 | 293 | 0.460 |
Why?
|
| MicroRNAs | 4 | 2024 | 518 | 0.460 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 760 | 0.430 |
Why?
|
| Yttrium Radioisotopes | 1 | 2013 | 4 | 0.410 |
Why?
|
| Humans | 29 | 2025 | 43102 | 0.390 |
Why?
|
| Doxorubicin | 1 | 2013 | 97 | 0.390 |
Why?
|
| Hippocampus | 8 | 2012 | 594 | 0.390 |
Why?
|
| Cells, Cultured | 9 | 2011 | 1621 | 0.370 |
Why?
|
| Proteins | 4 | 2011 | 382 | 0.350 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2013 | 163 | 0.350 |
Why?
|
| Apoptosis | 6 | 2007 | 1568 | 0.340 |
Why?
|
| Ubiquitination | 1 | 2011 | 62 | 0.340 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 224 | 0.330 |
Why?
|
| Embryo, Mammalian | 1 | 2011 | 157 | 0.330 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2011 | 91 | 0.320 |
Why?
|
| Gene Expression Profiling | 4 | 2025 | 704 | 0.320 |
Why?
|
| Male | 24 | 2025 | 23409 | 0.310 |
Why?
|
| Mice | 17 | 2024 | 6644 | 0.310 |
Why?
|
| Fibroblasts | 1 | 2011 | 281 | 0.300 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 1 | 2009 | 15 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2007 | 152 | 0.290 |
Why?
|
| Middle Aged | 8 | 2025 | 12222 | 0.280 |
Why?
|
| Neuroprotective Agents | 4 | 2018 | 269 | 0.280 |
Why?
|
| Down-Regulation | 1 | 2009 | 456 | 0.260 |
Why?
|
| Adult | 9 | 2025 | 13872 | 0.250 |
Why?
|
| Synapses | 1 | 2008 | 185 | 0.250 |
Why?
|
| Gene Library | 1 | 2025 | 62 | 0.230 |
Why?
|
| Cell Death | 7 | 2008 | 278 | 0.230 |
Why?
|
| Young Adult | 3 | 2025 | 5080 | 0.230 |
Why?
|
| Parkinson Disease | 1 | 2007 | 210 | 0.230 |
Why?
|
| Sialoglycoproteins | 1 | 2005 | 14 | 0.230 |
Why?
|
| Rats, Sprague-Dawley | 11 | 2016 | 1766 | 0.230 |
Why?
|
| Caspases | 2 | 2002 | 148 | 0.220 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2005 | 52 | 0.220 |
Why?
|
| Retrospective Studies | 2 | 2025 | 2544 | 0.220 |
Why?
|
| Renin-Angiotensin System | 1 | 2024 | 48 | 0.220 |
Why?
|
| Genetics, Population | 1 | 2025 | 121 | 0.220 |
Why?
|
| Astronauts | 1 | 2024 | 6 | 0.220 |
Why?
|
| Lymph Nodes | 1 | 2024 | 74 | 0.220 |
Why?
|
| Cosmic Radiation | 1 | 2024 | 5 | 0.220 |
Why?
|
| Space Flight | 1 | 2024 | 17 | 0.210 |
Why?
|
| Epilepsy, Temporal Lobe | 3 | 2012 | 18 | 0.210 |
Why?
|
| Female | 11 | 2025 | 24698 | 0.210 |
Why?
|
| Viral Proteins | 1 | 2025 | 190 | 0.210 |
Why?
|
| Evolution, Molecular | 1 | 2025 | 307 | 0.200 |
Why?
|
| Zebrafish | 1 | 2024 | 146 | 0.200 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 3 | 2011 | 108 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2011 | 105 | 0.190 |
Why?
|
| RNA, Messenger | 2 | 2025 | 1271 | 0.190 |
Why?
|
| Glycine | 1 | 2022 | 47 | 0.190 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2004 | 166 | 0.190 |
Why?
|
| Brain Diseases | 1 | 2002 | 31 | 0.180 |
Why?
|
| Peptide Hydrolases | 1 | 2002 | 44 | 0.180 |
Why?
|
| Cohort Studies | 2 | 2025 | 1759 | 0.180 |
Why?
|
| Actins | 1 | 2022 | 164 | 0.180 |
Why?
|
| DNA, Mitochondrial | 2 | 2018 | 191 | 0.170 |
Why?
|
| DNA Repair | 2 | 2018 | 198 | 0.170 |
Why?
|
| Neuroglia | 1 | 2002 | 133 | 0.170 |
Why?
|
| Analysis of Variance | 4 | 2012 | 575 | 0.160 |
Why?
|
| Dynamins | 1 | 2020 | 16 | 0.160 |
Why?
|
| In Situ Nick-End Labeling | 3 | 2006 | 138 | 0.160 |
Why?
|
| Phosphorylation | 4 | 2020 | 986 | 0.160 |
Why?
|
| Chemokine CXCL13 | 1 | 2019 | 18 | 0.160 |
Why?
|
| Receptors, CXCR5 | 1 | 2019 | 15 | 0.160 |
Why?
|
| Cycloheximide | 3 | 2009 | 30 | 0.150 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2018 | 21 | 0.150 |
Why?
|
| Gene Expression Regulation | 4 | 2021 | 1070 | 0.150 |
Why?
|
| Time Factors | 3 | 2009 | 1857 | 0.150 |
Why?
|
| Reperfusion Injury | 1 | 2018 | 58 | 0.140 |
Why?
|
| Status Epilepticus | 2 | 2008 | 15 | 0.140 |
Why?
|
| Blotting, Western | 5 | 2012 | 883 | 0.140 |
Why?
|
| Child, Preschool | 1 | 2022 | 1546 | 0.140 |
Why?
|
| Military Medicine | 1 | 2017 | 8 | 0.140 |
Why?
|
| Protein Synthesis Inhibitors | 2 | 2009 | 20 | 0.130 |
Why?
|
| Aged | 3 | 2025 | 8214 | 0.130 |
Why?
|
| Animals, Newborn | 2 | 2009 | 352 | 0.130 |
Why?
|
| Mitochondria | 4 | 2024 | 523 | 0.130 |
Why?
|
| DNA, Complementary | 1 | 2017 | 196 | 0.130 |
Why?
|
| Signal Transduction | 4 | 2019 | 2157 | 0.130 |
Why?
|
| Glucose | 2 | 2009 | 244 | 0.130 |
Why?
|
| Cerebral Cortex | 2 | 2009 | 306 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2012 | 220 | 0.120 |
Why?
|
| Military Personnel | 1 | 2017 | 110 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 611 | 0.120 |
Why?
|
| Brain Injuries | 1 | 2017 | 129 | 0.120 |
Why?
|
| Nuclear Proteins | 5 | 2004 | 333 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2019 | 1604 | 0.110 |
Why?
|
| United States | 2 | 2025 | 5205 | 0.110 |
Why?
|
| Carrier Proteins | 3 | 2008 | 321 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2008 | 200 | 0.110 |
Why?
|
| Sleep | 1 | 2016 | 185 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2017 | 760 | 0.110 |
Why?
|
| Immunohistochemistry | 3 | 2006 | 934 | 0.110 |
Why?
|
| Enzyme Inhibitors | 3 | 2008 | 458 | 0.110 |
Why?
|
| Risk Factors | 1 | 2022 | 3994 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3156 | 0.110 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 2004 | 41 | 0.100 |
Why?
|
| Capsules | 1 | 2013 | 28 | 0.100 |
Why?
|
| Mutation | 2 | 2025 | 1177 | 0.100 |
Why?
|
| Genome, Viral | 2 | 2025 | 119 | 0.100 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 62 | 0.100 |
Why?
|
| Delayed-Action Preparations | 1 | 2013 | 74 | 0.100 |
Why?
|
| Sclerosis | 1 | 2012 | 5 | 0.090 |
Why?
|
| Killifishes | 1 | 2012 | 2 | 0.090 |
Why?
|
| Ribonuclease III | 1 | 2012 | 10 | 0.090 |
Why?
|
| Autophagy | 1 | 2013 | 140 | 0.090 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2012 | 25 | 0.090 |
Why?
|
| Cricetinae | 2 | 2023 | 241 | 0.090 |
Why?
|
| Embryo, Nonmammalian | 1 | 2012 | 59 | 0.090 |
Why?
|
| Calcium | 2 | 2020 | 491 | 0.090 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2011 | 43 | 0.090 |
Why?
|
| DNA Glycosylases | 2 | 2018 | 17 | 0.090 |
Why?
|
| Adaptation, Physiological | 1 | 2012 | 143 | 0.080 |
Why?
|
| Infarction, Middle Cerebral Artery | 4 | 2020 | 78 | 0.080 |
Why?
|
| Carcinogens | 1 | 2011 | 126 | 0.080 |
Why?
|
| Microarray Analysis | 2 | 2008 | 64 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2019 | 1092 | 0.080 |
Why?
|
| Caspase 7 | 3 | 2007 | 18 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 2 | 2006 | 22 | 0.080 |
Why?
|
| Hyperthermia, Induced | 1 | 2009 | 28 | 0.070 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2009 | 64 | 0.070 |
Why?
|
| Cytoprotection | 1 | 2008 | 36 | 0.070 |
Why?
|
| Protein Kinases | 2 | 2007 | 100 | 0.070 |
Why?
|
| Vitamin A | 1 | 2008 | 86 | 0.070 |
Why?
|
| Models, Biological | 2 | 2009 | 712 | 0.070 |
Why?
|
| Carbocyanines | 1 | 2008 | 14 | 0.070 |
Why?
|
| Mice, Knockout | 3 | 2020 | 1035 | 0.070 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2007 | 9 | 0.070 |
Why?
|
| Hypoxia, Brain | 1 | 2007 | 7 | 0.070 |
Why?
|
| Microfilament Proteins | 1 | 2008 | 72 | 0.070 |
Why?
|
| Inflammation | 2 | 2024 | 758 | 0.070 |
Why?
|
| Cerebrovascular Circulation | 2 | 2007 | 70 | 0.070 |
Why?
|
| Protein Binding | 1 | 2011 | 1082 | 0.070 |
Why?
|
| Patch-Clamp Techniques | 1 | 2008 | 228 | 0.070 |
Why?
|
| Membrane Potentials | 1 | 2008 | 222 | 0.070 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 98 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2007 | 384 | 0.070 |
Why?
|
| Dizocilpine Maleate | 1 | 2007 | 43 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 88 | 0.060 |
Why?
|
| Disease Models, Animal | 5 | 2018 | 1596 | 0.060 |
Why?
|
| Nerve Degeneration | 2 | 2004 | 111 | 0.060 |
Why?
|
| Leupeptins | 1 | 2006 | 12 | 0.060 |
Why?
|
| Propidium | 1 | 2006 | 20 | 0.060 |
Why?
|
| Butadienes | 1 | 2006 | 29 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2006 | 196 | 0.060 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2006 | 41 | 0.060 |
Why?
|
| Kainic Acid | 4 | 2008 | 48 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 56 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2005 | 299 | 0.060 |
Why?
|
| Lamins | 2 | 2002 | 5 | 0.060 |
Why?
|
| Caspase 6 | 2 | 2002 | 5 | 0.060 |
Why?
|
| Lamin Type A | 2 | 2002 | 14 | 0.060 |
Why?
|
| Immunoblotting | 1 | 2006 | 181 | 0.060 |
Why?
|
| Staurosporine | 2 | 2002 | 38 | 0.060 |
Why?
|
| Nitriles | 1 | 2006 | 81 | 0.060 |
Why?
|
| Neuronal Plasticity | 1 | 2007 | 126 | 0.060 |
Why?
|
| Lipopolysaccharides | 1 | 2007 | 239 | 0.060 |
Why?
|
| Mediastinum | 1 | 2024 | 6 | 0.060 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 54 | 0.060 |
Why?
|
| Osteopontin | 1 | 2005 | 46 | 0.050 |
Why?
|
| Reperfusion | 2 | 2018 | 14 | 0.050 |
Why?
|
| Oligopeptides | 1 | 2005 | 109 | 0.050 |
Why?
|
| Glioma | 2 | 2002 | 96 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2002 | 508 | 0.050 |
Why?
|
| Radiation Injuries | 1 | 2024 | 23 | 0.050 |
Why?
|
| Temporal Lobe | 1 | 2004 | 26 | 0.050 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2024 | 40 | 0.050 |
Why?
|
| Small Molecule Libraries | 1 | 2024 | 62 | 0.050 |
Why?
|
| Embryonic Development | 1 | 2024 | 83 | 0.050 |
Why?
|
| Phenotype | 1 | 2007 | 780 | 0.050 |
Why?
|
| Hibernation | 1 | 2003 | 7 | 0.050 |
Why?
|
| Erythrocytes | 1 | 2024 | 126 | 0.050 |
Why?
|
| Genes, Mitochondrial | 1 | 2023 | 14 | 0.050 |
Why?
|
| Rodentia | 1 | 2023 | 47 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2003 | 37 | 0.050 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2003 | 21 | 0.050 |
Why?
|
| Pyramidal Cells | 1 | 2003 | 65 | 0.050 |
Why?
|
| Ischemic Attack, Transient | 1 | 2003 | 22 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2003 | 127 | 0.050 |
Why?
|
| Thiolester Hydrolases | 1 | 2022 | 7 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2025 | 430 | 0.050 |
Why?
|
| Indians, North American | 1 | 2025 | 192 | 0.050 |
Why?
|
| RNA, Untranslated | 1 | 2022 | 50 | 0.050 |
Why?
|
| Immunity | 1 | 2022 | 61 | 0.050 |
Why?
|
| Ferrets | 1 | 2021 | 14 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 3 | 2016 | 1869 | 0.040 |
Why?
|
| Caspase 3 | 1 | 2002 | 227 | 0.040 |
Why?
|
| Glycolysis | 1 | 2021 | 71 | 0.040 |
Why?
|
| ROC Curve | 1 | 2021 | 159 | 0.040 |
Why?
|
| Mitochondrial Proteins | 1 | 2022 | 118 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 161 | 0.040 |
Why?
|
| Gene Expression | 1 | 2003 | 701 | 0.040 |
Why?
|
| Lung | 1 | 2023 | 492 | 0.040 |
Why?
|
| Protein Phosphatase 2 | 1 | 2020 | 26 | 0.040 |
Why?
|
| Superoxides | 1 | 2020 | 57 | 0.040 |
Why?
|
| Systems Theory | 1 | 2019 | 4 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2002 | 386 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2021 | 195 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2019 | 87 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2004 | 735 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2019 | 207 | 0.040 |
Why?
|
| Proteomics | 1 | 2021 | 378 | 0.040 |
Why?
|
| Thrombolytic Therapy | 1 | 2018 | 23 | 0.040 |
Why?
|
| Homeostasis | 1 | 2020 | 192 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 149 | 0.040 |
Why?
|
| Disease Progression | 1 | 2019 | 667 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 2 | 2006 | 13 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2008 | 310 | 0.030 |
Why?
|
| Antibodies | 2 | 2007 | 144 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 2853 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 968 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2012 | 20 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 2676 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2012 | 44 | 0.020 |
Why?
|
| Cell Nucleus | 2 | 2004 | 383 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2004 | 536 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 411 | 0.020 |
Why?
|
| Computational Biology | 1 | 2012 | 327 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2008 | 36 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2008 | 61 | 0.020 |
Why?
|
| Receptors, Neurotransmitter | 1 | 2008 | 23 | 0.020 |
Why?
|
| Ion Channels | 1 | 2008 | 74 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2008 | 169 | 0.020 |
Why?
|
| Vitamins | 1 | 2008 | 81 | 0.020 |
Why?
|
| Long-Term Potentiation | 1 | 2008 | 109 | 0.020 |
Why?
|
| Middle Cerebral Artery | 1 | 2007 | 14 | 0.020 |
Why?
|
| Caspase 9 | 1 | 2007 | 30 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2007 | 48 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 83 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2007 | 98 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2007 | 138 | 0.020 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2007 | 81 | 0.020 |
Why?
|
| Postmortem Changes | 1 | 2006 | 18 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 2007 | 43 | 0.020 |
Why?
|
| Solubility | 1 | 2007 | 139 | 0.020 |
Why?
|
| Caspase 8 | 1 | 2006 | 32 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2006 | 77 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2007 | 159 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1124 | 0.010 |
Why?
|
| Indoles | 1 | 2006 | 187 | 0.010 |
Why?
|
| Denervation | 1 | 2004 | 27 | 0.010 |
Why?
|
| Bleeding Time | 1 | 2003 | 5 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2004 | 78 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2004 | 89 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2004 | 39 | 0.010 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2003 | 16 | 0.010 |
Why?
|
| 14-3-3 Proteins | 1 | 2003 | 21 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2003 | 17 | 0.010 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 2003 | 7 | 0.010 |
Why?
|
| Uracil-DNA Glycosidase | 1 | 2003 | 4 | 0.010 |
Why?
|
| DNA Ligases | 1 | 2003 | 13 | 0.010 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2003 | 23 | 0.010 |
Why?
|
| Endodeoxyribonucleases | 1 | 2003 | 28 | 0.010 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2003 | 92 | 0.010 |
Why?
|
| Protein Transport | 1 | 2004 | 296 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2003 | 49 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2004 | 171 | 0.010 |
Why?
|
| Convulsants | 1 | 2002 | 5 | 0.010 |
Why?
|
| Diazepam | 1 | 2002 | 10 | 0.010 |
Why?
|
| GABA Agonists | 1 | 2002 | 21 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2002 | 52 | 0.010 |
Why?
|
| Microinjections | 1 | 2002 | 50 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2002 | 87 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 455 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 224 | 0.010 |
Why?
|
| Amygdala | 1 | 2002 | 125 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2002 | 462 | 0.010 |
Why?
|
| Hela Cells | 1 | 2002 | 376 | 0.010 |
Why?
|
| Cell Survival | 1 | 2003 | 945 | 0.010 |
Why?
|
| Adolescent | 1 | 2004 | 6081 | 0.010 |
Why?
|